Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.</li><li> The company announced its 1Q2025 preliminary financial results.</li><li> The company continues to execute at a high level by posting record 1Q revenue and continued growth in earnings.</li></ul>

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 1Q2025 preliminary financial results. The company continues to execute at a high level by posting record 1Q revenue and continued growth in earnings.

<ul><li>BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.</li><li> The company announced its 4Q and full year 2024 results.</li><li> The company continues to execute at a high level by posting record revenue and earnings that beat expectations.</li></ul>

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 4Q and full year 2024 results. The company continues to execute at a high level by posting record revenue and earnings that beat expectations.

BSEM: Revenue and Earnings Blow Away Estimates

<ul><li>BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.</li><li> The company continues to advance its therapies, with the company's BioRetain product receiving approval for a clinical study for the treatment of venous leg ulcers.</li></ul>

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company continues to advance its therapies, with the company's BioRetain product receiving approval for a clinical study for the treatment of venous leg ulcers.

BSEM: Company Receives Approval to Advance Trial

<ul><li>BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.</li><li> The company's stock has suffered the last few days, largely, it seems, due to two of its major products not being on the just released LCD coverage list.</li><li>There's more to the story, and we reiterate our recently upgraded price target.</li></ul>

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company's stock has suffered the last few days, largely, it seems, due to two of its major products not being on the just released LCD coverage list.There's more to the story, and we reiterate our recently upgraded price target.

United States

BioStem Technologies, Inc. is a regenerative medicine company. The Company focuses on the stem cell industry for treatment in a range of rare and common degenerative diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BioStem Technologies (BSEM US)

BSEM: Growth Continues to Impress

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

BSEM: Growth Continues to Impress

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

BSEM: Revenue and Earnings Blow Away Estimates

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

BSEM: Company Receives Approval to Advance Trial

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

BSEM: Digging Into Medicare Issue

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)